Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025

Seres Therapeutics, Inc.

Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.
Marella Thorell (EVP/CFO) and Thomas DesRosier (EVP/CLO) appointed Co-CEOs and Co-Presidents effective Aug 1, 2025.
Shaff to receive prorated 2025 bonus; Board may accelerate payment if a strategic transaction closes before year-end.
Thorell and DesRosier each receive $500,000 appointment bonus: one-third on Aug 1, 2025, balance on Jan 1, 2026 subject to retention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.